BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Anastrozole: trial readouts and FDA decisions
2 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 2 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Tolmar Inc., Olema Oncology, Inc., AstraZeneca, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Olema Oncology, Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2027-01-30 est. | P3 | Tolmar Inc. | NCT04906395 Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | Breast Cancer | active not recruiting | 250 |
| 2026-12 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05780567 Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Canc | Breast Cancer | active not recruiting | 1946 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-31 est. | P3 | Olema Oncology, Inc. OLMA | NCT06016738 OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Neg | active not recruiting | 510 |
| 2026-06-26 | P3 | AstraZeneca AZN | NCT04711252 A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Receiv | ER-Positive HER2-Negative Breast Cancer | active not recruiting | 1371 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.